Gene editing stocks are still exploding higher.
- CRISPR Therapeutics (CRSP) is up another $11 to $161.70
- Editas Medicine (EDIT) is up another $7.70 to $53.80
- Intellia Therapeutics (NTLA) is up another $31 to $182.72
- Beam Therapeutics (BEAM) is up another $16 to $127.13
All thanks to NTLA, which jumped after releasing “interim data from the Phase 1 trial of its collaboration with Regeneron on an experimental therapy for transthyretin amyloidosis (ATTR) – a protein misfolding disorder,” as noted in a company press release.
“The data showed that for the six people that received a single 0.3 mg/kg dose of NTLA-2001, there was an 87% mean reduction in serum TTR, while there was a maximum 96% serum TTR reduction following a month’s treatment,” the company added.
The best part – all of the stocks noted above could see higher highs.
Better, “Intellia’s gene editing results decisively exceeded analyst expectations, launching the rest of the field into the spotlight overnight and maybe, just maybe, providing some fodder for the FDA to lighten up on its resistance to hosting gene editing trials in the U.S.,” reported FierceBiotech. The results were a pretty big deal.
With further progress, we could be looking at a massive game changer here.
The post This is Why Gene Editing Stocks Could Race to Higher Highs appeared first on Morningology.
